Aldeyra Therapeutics company information, Employees & Contact Information

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules Business Wire

FDA accepts reproxalap new drug application for dry eye disease again Healio

Aldeyra Therapeutics Resubmits Reproxalap NDA in Dry Eye Disease HCPLive

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data Seeking Alpha

FDA Reviews Breakthrough Dry Eye Drug: Aldeyra's Reproxalap Could Transform Treatment Landscape Stock Titan

Reproxalap Improves Ocular Discomfort in Second Dry Eye Chamber Trial Ophthalmology Advisor

Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease The American Journal of Managed Care® (AJMC®)

Aldeyra Therapeutics hits primary end point in 1 of 2 phase 3 trials for reproxalap Optometry Times

FDA Accepts Reproxalap Application for Dry Eye Disease HCPLive

Intravitreal Methotrexate Fast Tracked for Retinitis Pigmentosa Ophthalmology Advisor

Aldeyra Therapeutics Is Severely Undervalued Before PDUFA Seeking Alpha

Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal Stock Titan

FDA accepts for review Aldeyra Therapeutics’ resubmitted New Drug Application for reproxalap Ophthalmology Times

FDA Issues Complete Response Letter to Reproxalap for Dry Eye Disease HCPLive

US FDA declines to approve Aldeyra's eye disease drug Reuters

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap Business Wire

Aldeyra Therapeutics receives Special Protocol Assessment Agreement Letter from FDA for ADX-2191 Ophthalmology Times

Reproxalap Faces Third FDA Review for Dry Eye Disease Ophthalmology Advisor

Aldeyra submits third new drug application for reproxalap for the treatment of dry eye disease Ophthalmology Times

JonesTrading Lifts Aldeyra Therapeutics, Inc. (ALDX) Price Target to $9 Yahoo Finance

Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? Yahoo Finance

FDA accepts Aldeyra's resubmitted reproxalap NDA Eyes On Eyecare

Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership (ALDX) Seeking Alpha

Aldeyra Therapeutics receives complete response letter from FDA for reproxalap NDA Ophthalmology Times

Aldeyra hopes new data for dry-eye disease drug will satisfy FDA FirstWord Pharma

Aldeyra Therapeutics Stock Craters to All-Time Low on FDA Letter Investopedia

EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies Ophthalmology Times Europe

Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference Business Wire

Aldeyra shuffles RASP pack, dropping and swapping assets in response to data Fierce Biotech

Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity Seeking Alpha

Aldeyra says dry eye therapy undergoes FDA review (ALDX:NASDAQ) Seeking Alpha

Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra Business Wire

Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After GlobeNewswire

Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY-2 Trial in Patients with Dry Eye Disease Stock Titan

Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights Business Wire

ALDX INVESTIGATION: Aldeyra Therapeutics (NASDAQ:ALDX) GlobeNewswire

Aldeyra reports positive phase 3 data on reproxalap for DED Eyes On Eyecare

Don't Ignore The Insider Selling In Aldeyra Therapeutics simplywall.st

Market Sentiment Around Loss-Making Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) simplywall.st

FDA Accepts Aldeyra’s Reproxalap Application for Review TipRanks

Aldeyra’s FDA Resubmission And AbbVie Option Revitalize Reproxalap’s Prospects (ALDX) Seeking Alpha

Awaiting FDA's decision, Aldeyra's dry eye disease drug scores phase 3 win for conjunctivitis Fierce Biotech

Aldeyra Therapeutics, AbbVie enter option agreement to develop reproxalap Healio

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry? simplywall.st

Aldeyra Therapeutics Reports First-Quarter 2021 Financial Results and Recent Business Highlights citybiz

Aldeyra: A Speculative Buy Amid Reproxalap's NDA Resubmission Seeking Alpha

Biotech Shake-Up: Aldeyra Therapeutics & Others Feel The Heat Finimize

Phase 2 Trial of ADX-629 Underway for Treatment of AD Dermatology Times

ADC Therapeutics, Aldeyra start off New Year with program discontinuations Fierce Biotech

Milestone resubmits new drug application while Aldeyra readies similar 2nd-chance filing Fierce Biotech

Aldeyra Resubmits Reproxalap NDA to FDA TipRanks

Reviewing what is in the anterior segment topical ophthalmic pipeline Optometry Times

Aldeyra Stock Slumps After FDA Says Drug Candidate For Dry Eyes Treatment Failed To Show Efficacy – Retail Stays Optimistic Stocktwits

Aldeyra Therapeutics to Present at HC Wainwright Global Investment Conference FinancialContent

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA FinancialContent

Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights FinancialContent

Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial PR Newswire

Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy FinancialContent

Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference FinancialContent

What's Going On With Aldeyra Therapeutics Stock? Benzinga

A look at the latest and upcoming pharmaceutical patents Optometry Times

Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis MarketBeat

Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules NewsBreak: Local News & Alerts